A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
A study presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) found that there was no clinically meaningful difference when patients with breast cancer were switched from treatment with reference filgrastim (Neupogen) to EP2006, the first FDA-approved filgrastim biosimilar (marketed as Zarxio).
The phase 3, randomized, double-blind registration study sought to assess the safety and efficacy of alternating treatment with EP2006 and the reference filgrastim for the prevention of severe neutropenia in patients undergoing myelosuppressive chemotherapy in the neoadjuvant setting.
The study comprised 218 patients who received the reference filgrastim or its biosimilar together with 6 cycles of chemotherapy. The patients were randomized into 4 arms; 2 arms received only 1 of the treatment products, either the EP2006 or the reference, and did not switch treatments. 2 arms received alternating treatments of the biosimilar and reference product (or vice versa) over cycles 1 to 6. The analysis compared the safety and efficacy of the 2 treatments between the pooled switched groups and the unswitched reference group over cycles 2 to 6. The researchers pre-defined a margin with a 95% confidence interval (CI), to demonstrate non-inferiority of the biosimilar product in febrile neutropenia (FN) rates between the switched an unswitched groups, for treatment cycles 2 to 6.
A total of 107 patients switched treatment, while 51 patients received the reference product in all cycles. Baseline characteristics were similar between the 2 treatment groups. The incidence of FN for the switched group was 3.4%, compared with 0% in the group that received the reference product alone (95% CI, range -9.65 to 4.96), a rate that fell within the pre-defined margin. Only 1 patient (switched group) was hospitalized due to FN. Infections were noted in 9.3% of the switched group versus 9.9% of the reference group. Treatment emergent adverse events were reported in 42.1% of patients in the switched group versus 39.2% of the reference group. Musculoskeletal and connective tissue disorders related to treatment with filgrastim were noted in 35.5% of the switched group versus 39.2% of the reference group. No patients developed anti-drug antibodies during the study period.
The researchers concluded that there was no evidence of clinically meaningful differences when patients undergoing treatment for breast cancer were switched between biosimilar filgrastim and reference filgrastim, or vice versa.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
EHA Poster Shows Transfusion Avoidance Rates Were Comparable Between Eculizumab Biosimilar, Soliris
Published: June 15th 2024 | Updated: June 14th 2024A poster from the European Hematology Association’s (EHA) 2024 annual meeting in Madrid, Spain, showed similar rates of transfusion avoidance between patients with paroxysmal nocturnal hemoglobinuria who were administered reference eculizumab (Soliris) and those administered an eculizumab biosimilar (SB12).
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Posters Capture Clinical Impacts of Infliximab in Super-Responders, Pregnant Patients With IBD
June 1st 2024Posters from Digestive Disease Week 2024 look at how super-responders and pregnant patients with inflammatory bowel disease (IBD) react to treatment with subcutaneous infliximab and an infliximab biosimilar, respectively.